An observational study in Multiple Sclerosis, sponsored by University of Oxford. Enrolling by invitation at 1 site in United Kingdom. Open to participants aged Up to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-28.
Sponsored by University of Oxford · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 252 studies in Multiple Sclerosis with a site in United Kingdom — 28 open to participants now, 46 under way, 11 of them phase 3. Multiple Sclerosis · United Kingdom.
Among the 252 studies in Multiple Sclerosis with a site in United Kingdom, this one is the 25th largest by planned enrollment of the 57 observational ones that give a count, is one of 16 that started in 2021, is one of 57 observational ones, reaches primary completion later than 22 of the 45 other live ones, and was the 238th registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →28 of the 252 studies in Multiple Sclerosis with a site in United Kingdom are open now. Recruiting first, the newest first:
Imperial College London · Sites in United Kingdom
Ages 18+
Aston University · Sites in United Kingdom
Ages 2–16 · Healthy volunteers
Swansea University · Sites in United Kingdom
Ages 18+
AstraZeneca · Sites in United Kingdom, United States, Australia and 2 more countries
Ages 18–60
Oxford University Hospitals NHS Trust · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: Up to 99 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
252 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 47 · Phase 3 72 · Phase 4 15
First in 1999; this study’s year is marked. 16 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is above the median of 100 across 972 observational studies indexed under Multiple Sclerosis.
Median enrollment 136 across the 195 interventional studies, 200 across the 57 observational. Of the 187 that completed or were terminated, 95 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
154 of 252 have an industry lead sponsor. The 10 most frequent:
University of Oxford is the lead sponsor of 813 studies on the registry; 119 are open to participants now.
University of Oxford has 2 studies filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
11 of the studies in Multiple Sclerosis with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT06274671University of ExeterGlymphatic MRI in Clinically Isolated Syndrome | 2026-12-31 |
| NCT07452562Swansea UniversityHesperidin RCT in MS | 2027-01-18 |
| NCT07111637Queen Mary University of LondonArtificial Intelligence-Assisted Magnetic Resonance Imaging for Quality, Efficiency and Equity in the National Health Service (NHS) Care of Multiple Sclerosis | 2027-04-14 |
| NCT06900244University of OxfordMetabolic Imaging of Neurological Disease | 2027-06 |
Add all 11 to your calendar (.ics) → With an account.
Among the 252 studies in Multiple Sclerosis with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Multiple Sclerosis is a chronic condition that shows changes in the way that the brain consumes sugar. It is also known that there are a number of metabolic and inflammatory sequelae following a transient ischemic attack/stroke (hereby referred to collectively as 'stroke'). This study will use a powerful new technology ('hyperpolarised magnetic resonance imaging') to detect these changes in the brains of people with multiple sclerosis and Clinically Isolated Syndrome (CIS) or following a stroke when compared to a group of healthy volunteers. It will be undertaken at the University of Oxford, and each participant will undergo up to 4 scans over the course of three years.
Healthy volunteers and people with MS / stroke
Exclusion Criteria:
-
All phenotypes
To detect 13C metabolism in healthy participants and MS, CIS, and Stroke patients.
Baseline: Imaging of 13C labelled downstream metabolites from the injected metabolically active substrates in healthy participants and MS/CIS/Stroke patients, and compare to healthy volunteers
Time frame: Baseline
Plan to share: Yes — Upon reasonable request
No publications or documents are linked to this record.
Started Jul 2021 (actual). Primary completion is estimated for Jun 2027, 71 months after the start.
Of 336 non-industry observational studies under Multiple Sclerosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 81. This study's planned 71 months is above that.
Counting every sponsor, half of 427 studies reached it within 41 months; a quarter within 15 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.